Conversations in Drug Development Trends

JUNE 13, 2024

The FDA Oncology Center of Excellence (OCE) is committed to further enhancing oncology research and as a result, has recently implemented several projects aimed to revolutionize oncology clinical trials. Find key highlights from the webinar below, and check out the webinar for a full overview!

Trials 52

Trials Clinical Trials Drug Development Clinical Development 52

Conversations in Drug Development Trends

FEBRUARY 26, 2024

With the necessary prioritization of various factors when designing your clinical trial, the patient experience can be overlooked or improperly addressed in study design. However, incorporating the patient experience into your design is one of the best ways to ensure your drug development program is a commercial success.

Clinical Trials 59

Clinical Trials Trials Disease Clinical Research 59

Conversations in Drug Development Trends

MAY 1, 2024

This process can be daunting, but understanding how to manage feedback effectively is crucial for developing and ultimately gaining approval for new therapies, especially in oncology clinical trials. Each nation has varying definitions of what qualifies as a pivotal study.

Clinical Research 69

Clinical Research Trials Clinical Trials Research 69

The Pharma Data

SEPTEMBER 15, 2020

Find out solutions to mitigate the impact from clinical supply chain risk and discover how to improve dynamic drug supply forecasting strategies. Join this webinar to learn how supply forecasting and interactive response technology can help biotech companies improve supply planning and distribution while reducing cost and risk.

Clinical Supply 52

Clinical Supply Clinical Trials Doctors Clinical Development 52

Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

Alta Sciences

JUNE 9, 2023

Accelerating Global Drug Development Timelines With Ethnobridging rmaloney Mon, 06/12/2023 - 16:07 HTML Safe Strategy to Save Time and Money Avoid repeating Phase I studies for drugs intended for the Asian market. Download your copy today. In this complimentary webinar , Mel B. Watch the webinar.

Drug Development 40

Drug Development Clinical Trials Biosimilars Pharmacokinetics 40

LifeSciVC

FEBRUARY 27, 2024

By Ivana Magovčević-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC Patients and their care partners are at the center of our work in the life sciences industry – but at what point during the drug development process should companies start to engage these key stakeholders?

Drug Development 64

Drug Development Disease Drugs Treatment 64

Conversations in Drug Development Trends

FEBRUARY 22, 2023

Our rare disease team at Worldwide will be hosting a panel discussion webinar with patient advocates active in Rare Disease Day events to synthesize the most salient conversations taking place. Panelists will answer questions such as: What are the greatest challenges holding patients back from enrolling in trials?

Disease 52

Disease Clinical Trials Trials Treatment 52

Conversations in Drug Development Trends

AUGUST 10, 2023

The event provided a unique opportunity to interact with a large and diverse group of fellow stakeholders, expanding my perspective on the impact of psychedelic clinical trials. Psychedelic Research at Worldwide Since 2017, Worldwide Clinical Trials have supported a myriad of sponsors leading the way in psychedelic research programs.

Science 98

Science Clinical Trials Trials Clinical Research 98

Fierce BioTech

JULY 17, 2023

Best practices for capturing reproducible and accurate in vivo data to reduce failure in clinical trials – the most expensive phase of drug development. Discussion will include: Current in vivo study management practices and processes. How did we get here?

Clinical Trials 88

Clinical Trials Drug Development Research Trials 88

Alta Sciences

JULY 25, 2024

Discover some of the nonclinical requirements for moving dermal studies into Phase I clinical trials, including formulation considerations, species selection, and ideal candidates for transdermal drug delivery systems (TDDS). Watch the webinar. Watch the webinar. Catch up on what you might have missed below!

Science 52

Science Clinical Trials Clinical Pharmacology FDA 52

Conversations in Drug Development Trends

NOVEMBER 14, 2022

But in a clinical trial setting, what role does a therapist play and how do they affect the clinical trial data? We connected with her to answer a few questions about how these roles function: When should a psychedelic trial utilize a therapist? This is called “psychedelic-assisted psychotherapy” (PAP).

Trials 59

Trials Clinical Trials Therapies Treatment 59

Alta Sciences

JANUARY 22, 2024

Get a Head Start On Your 2024 Preclinical Drug Development Program blussier Mon, 01/22/2024 - 15:18 HTML EXPERTISE Matters. With four strategically placed preclinical research facilities throughout North America, Altasciences can get your CTA/IND-enabling studies underway in just 8 weeks!

Drug Development 40

Drug Development Clinical Trials Drugs Trials 40

Cytel

APRIL 3, 2024

Thank you to Charlotta Gauffin, Chief Scientific Officer at Dicot, for joining us for our recent webinar, “The Road to First-in-Human Trials: Insights from a Real-World Example.” Thoughtfully and carefully planned nonclinical studies help pave a smooth path toward first-in-human Phase 1 clinical trials.

Clinical Trials 59

Clinical Trials Drugs Trials Drug Development 59

PPD

OCTOBER 16, 2023

” By tokenizing participants in a clinical trial, researchers gain the ability to link RWD from trial participants’ medical data to their clinical trial data. Tokenization can accelerate innovation in clinical trials and drug development. Here are five things you need to know about tokenization.

Clinical Trials 98

Clinical Trials Trials Research Therapies 98

Alta Sciences

MARCH 21, 2024

Top 5 Scientific Resources in CNS Clinical Trials blussier Thu, 03/21/2024 - 18:09 HTML CNS Center of Excellence Resource Library Altasciences has an extensive understanding of psychiatric and neurologic disorders, stemming from our decades of conducting complex studies in various therapeutic indications impacting the central nervous system.

Clinical Trials 40

Clinical Trials Trials Drug Development FDA 40

Alta Sciences

SEPTEMBER 29, 2023

If you have yet to visit our Montréal clinical facility to learn about the advantages of conducting trials in Canada or had the pleasure of meeting the friendly, uniquely talented, and experienced team working on your studies, you will want to watch our latest video.

Clinical Trials 52

Clinical Trials Trials Drug Development Drugs 52

Fierce BioTech

MARCH 12, 2024

For biopharma and biotech companies, FSP partnerships have emerged as a pivotal strategy for accessing the complementary expertise and resource flexibility they need to meet their timelines, and innovative providers are implementing new, globalized FSP strategies to keep their clients ahead of the curve.

Clinical Research 52

Clinical Research Drug Development Trials Research 52

Conversations in Drug Development Trends

FEBRUARY 28, 2023

Rob found out that in 1980, a researcher in Birmingham, England first synthesized a very niche cancer drug in a small lab. Over the next few decades, that drug made its way through clinical trials, securing approval in 2007—just 36 months before Rob was diagnosed in 2010. But what was truly remarkable?

Clinical Trials 52

Clinical Trials Disease Trials Research 52

Alta Sciences

AUGUST 7, 2024

blussier Wed, 08/07/2024 - 19:51 HTML Timing is Everything Early collaboration with an experienced CDMO is crucial in drug development to mitigate manufacturing risks and ensure the efficient formulation of your API for preclinical and clinical testing. Contact us today to discuss the next stage of your drug development journey.

Clinical Trials 40

Clinical Trials Compliance Drug Development Trials 40

Alta Sciences

JANUARY 24, 2024

Discover the Power of Driving Simulations for CNS Side-Effect Analysis blussier Wed, 01/24/2024 - 18:25 HTML Start Your Driving Trial Quickly—Simulators On-Site Driving simulator studies are a safe, efficient, and effective alternative to on-the-road driving trials for CNS-active drugs. jpg Tags Clinical Trials Weight 1

Clinical Trials 40

Clinical Trials Trials FDA Drug Development 40

Conversations in Drug Development Trends

JUNE 21, 2024

Worldwide Clinical Trials attends each year to hear from the research community, connect with our sponsors and sites, and explore potential partnerships to drive forward novel treatments. Check out this webinar on navigating the landscape of oncology clinical trials. Interested in hearing more insights from Matt?

Clinical Trials 64

Clinical Trials Therapies Clinical Research Immune Response 64

Alta Sciences

JULY 18, 2023

Webinar: Gene and Cell Therapy: Enhanced CNS and Ocular Delivery in Nonhuman Primates With the new modalities, early drug discovery may require more specialized and focused delivery options for animal disease models. There are several reasons why choosing Canada for your clinical trials can be beneficial. Read or listen.

Science 40

Science Clinical Trials FDA Trials 40

The Pharma Data

DECEMBER 15, 2020

Company plans to meet with regulatory authorities as it evaluates next development steps. Company to host Key Opinion Leader (KOL) webinar to discuss these results today, December 16, at 8:00 am EST; registration link below. months that we observed in this trial. TEL AVIV, Israel , Dec.

Clinical Trials 40

Clinical Trials Trials Treatment Therapies 40

Agency IQ

JULY 22, 2024

Facing headwinds, FDA moves ahead on diagnostics policy implementation but faces Congressional, legal, and judicial questions In April 2024, the FDA issued a final rule to update its regulatory approach to certain test products known as Laboratory Developed Tests (LDTs). AgencyIQ provides a status update for regulated industry.

FDA 40

FDA Laboratories Regulations Clinical Trials 40

Drug Target Review

DECEMBER 5, 2024

1 In 2017, the US Food and Drug Administration (FDA) approved the first AAV-based gene replacement therapy (Luxturna), for Leber congenital amaurosis type 2. The large number of ongoing clinical trials of recombinant AAV (rAAV)-based therapies highlights their promise for addressing a wide variety of human genetic disorders.

Therapies 52

Therapies Virus DNA Compliance 52

Agency IQ

AUGUST 23, 2024

The rule has significant implications for the way that LDTs are regulated in general, but also has additional impact on the use of LDTs in the context of drug development (i.e., There are several high-level takeaways from these updates for drug developers.

FDA 40

FDA Laboratories Clinical Trials Regulations 40

Agency IQ

AUGUST 2, 2024

September 30, 2024 Upcoming (or overdue) legislative requirements due as of August and September Congress often asks the FDA to release or hold guidance documents, regulation, reports, meetings, hearings or pilot programs as of specific dates.

FDA 40

FDA Science Regulations Biosimilars 40

Agency IQ

JUNE 29, 2023

.; Request To Revoke Color Additive Listing for Use of Titanium Dioxide in Food Proposed Rule July 3 Identification, Assessment, and Control of Nitrosamine Drug Substance-Related Impurities in Human Drug Products; Establishment of a Public Docket Request for Comments July 3 Methodological Challenges Related to Patient Experience Data; Request for Information (..)

FDA 40

FDA Science Regulations Production 40

Agency IQ

APRIL 12, 2024

In drug development, biochemical assays might be used to determine a product’s binding affinity to a target receptor of interest, along with the strength, stability and duration of the target-ligand complex after the product binds to the receptor. What does progressive implementation of a potency assurance strategy mean?

Production 40

Production FDA Therapies Biochemical Assays 40

Agency IQ

NOVEMBER 3, 2023

A trial run: The Covid-19 EUA transition. That transition could potentially serve as a trial run to the phased-in system under the proposed LDT rule in which a high volume of products would have a time-limited window to submit regulatory applications to the FDA. See AgencyIQ’s full discussion on this issue here.]

FDA 40

FDA Laboratories Regulations Production 40

PPD

APRIL 14, 2025

This expansion is creating opportunities for clinical trials related to a range of new therapy areas and their subpopulations. The SELECT trial set out to understand whether the drug has similar effect on patients without diabetes.

Clinical Trials 52

Clinical Trials Trials Clinical Development Disease 52

Agency IQ

OCTOBER 27, 2023

Start Date End Date Event Event Type Center 10/30/2023 10/30/2023 Defining ‘Candy-Like’ Nonprescription Drug Products Workshop CDER 10/31/2023 10/31/2023 Cellular, Tissue, and Gene Therapies Advisory Committee Advisory Committee Meeting CBER 10/31/2023 10/31/2023 Webinar – Proposed Rule: Medical Devices; Laboratory Developed Tests (..)

FDA 40

FDA Science Regulations Production 40

Agency IQ

JUNE 2, 2023

Title Type Comments Close Notification of a Permanent Discontinuance or Interruption in Manufacturing Under Section 506C of the Federal Food, Drug, and Cosmetic Act Guidance June 5 Patient Preference Information—Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in (..)

FDA 40

FDA Science Regulations Production 40

Agency IQ

MAY 3, 2024

Title Type Comments Close Key Information and Facilitating Understanding in Informed Consent Guidance for Sponsors, Investigators, and Institutional Review Boards Draft Guidance April 30 Early Alzheimer’s Disease: Developing Drugs for Treatment Draft Guidance May 13 Select Updates for the Premarket Cybersecurity Guidance: Section 524B of the (..)

FDA 40

FDA Science Regulations Clinical Trials 40

Agency IQ

JULY 8, 2024

Several webinars and training sessions are geared towards ISO identification of medicinal products (IDMP) standards which is referred to as Substance, Product, Organization, Referentials (SPOR) data management services. ’s Medicines and Healthcare products Regulatory Agency (MHRA).

Regulations 40

Regulations Pharmaceuticals Production Vaccine 40

Agency IQ

SEPTEMBER 29, 2023

Title Type Comments Close Classification Categories for Certain Supplements Under BsUFA III Guidance October 10 Formal Meetings Between the Food and Drug Administration and Sponsors or Applicants of Biosimilar User Fee Act Products Guidance October 10 QTc Information in Human Prescription Drug and Biological Product Labeling Guidance October 10 Postmarketing (..)

FDA 40

FDA Science Regulations Production 40